Combined platelet count with sCD163 and genetic variants optimizes esophageal varices prediction in cirrhotic patients

Journal of Gastroenterology and Hepatology (Australia)

Volumn 28, Issue 1, 2013, Pages 112-121

  Yang, Ying Ying ^a,c   Hou, Ming Chih ^a,c   Lin, Ming Wei ^b,c   Chen, Ping Hsien ^a,c   Liao, Wei Chih ^c,d   Chu, Chi Jen ^a,c   Lin, Han Chieh ^a,c  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b Institute of Public Health   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d TAIPEI MUNICIPAL GAN DAU HOSPITAL   (Taiwan)

Author keywords

Cirrhosis; Esophageal varices; Genetic polymorphism; Heme oxygenase 1; Vascular endothelial growth factor

Indexed keywords

CD163 ANTIGEN; HEME OXYGENASE 1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ADULT; ARTICLE; COHORT ANALYSIS; DIAGNOSTIC ACCURACY; ESOPHAGUS VARICES; ESOPHAGUS VARICES BLEEDING; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SPLENOMEGALY; THROMBOCYTE COUNT;

EID: 84871644598     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2012.07245.x     Document Type: Article

References (27)

1. Jensen DM. Endoscopic screening for varices in cirrhosis: findings, implications, and outcomes. Gastroenterology 2002; 122: 1620-1630.
2. Spiegel BMR, Esrailian E, Eisen G. The budget impact of endoscopic screening for esophageal varices in cirrhosis. Gastrointest. Endosc. 2007; 66: 679-692.
3. Bosch J, Berzigotti A, Barcia-Pagan JC, Abraldes JG. The management of portal hypertension: rational basis, available treatments and future options. J. Hepatol. 2008; 48: S68-92.
4. Berzigotti A, Gilabert R, Abraldes JG etal. Noninvasive prediction of clinically significant portal hypertension and esophageal varices in patients with compensated liver cirrhosis. Am. J. Gastroenterol. 2008; 103: 1159-1167.
5. Qamar AA, Grace ND, Groszmann RJ etal. Platelet count is not a predictor of the presence or development of gastroesophageal varices in cirrhosis. Hepatology 2008; 47: 153-159.
6. Schwarzenberger E, Meyer T, Golla V, Sahdala NP, Min AD. Utilization of platelet count spleen diameter ratio in predicting the presence of esophageal varices in patients with cirrhosis. J. Clin. Gastroenterol. 2010; 44: 146-150.
7. Coto E, Rodrigo L, Alvarez R etal. Variation at the angiotensin-converting enzyme and endothelial nitric oxide synthase genes is associated with the risk of esophageal varices among patients with alcoholic cirrhosis. J. Cardiovasc. Pharmacol. 2001; 38: 833-839.
8. D'Amico G, Pasta L, Madonia S etal. The incidence of esophageal varices in cirrhosis. Gastroenterology 2001; 120: A2.
9. Merli M, Nicolini G, Angeloni S etal. Incidence and natural history of small esophageal varices in cirrhotic patients. J. Hepatol. 2003; 38: 266-272.
10. Fernandez M, Mejias M, Angermayr B, Garcia-Pagan JC, Rodés J, Bosch J. Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats. J. Hepatol. 2005; 43: 98-103.
11. Fernandez M, Lambrecht RW, Bonkovsky HL. Increased heme oxygenase activity in splanchnic organs from portal hypertensive rats: role in modulating mesenteric vascular reactivity. J. Hepatol. 2001; 34: 812-817.
12. Dulak J, Deshane J, Jozkowicz A, Agarwal A. Heme oxygenase-1 and carbon monoxide in vascular pathobiology: focus on angiogenesis. Circulation 2008; 117: 231-241.
13. Møller HJ, Grønbeæk H, Schiødt FV etal. Soluble CD163 from activated macrophages predicts mortality in acute liver failure. J. Hepatol. 2007; 47: 671-676.
14. Holland-Fischer P, Grønbeæk H, Sandahi TD etal. Kupper cells are activated in cirrhotic portal hypertension and not normalized by TIPS. Gut 2011; 60: 1389-1393.
15. Chen YH, Chan LY, Lin MW etal. Heme oxygenase-1 gene promoter micro satellite variant is associated with angiographic restenosis after coronary stenting. Eur. Heart J. 2004; 25: 39-47.
16. Lin CC, Yang WC, Lin SJ etal. Length variant in heme oxygenase-1 is associated with arteriovenous fistula patency in hemodialysis patients. Kidney Int. 2006; 9: 65-72.
17. Watson CT, Webb NJ, Bottomley MJ, Brenchley PE. Identification of variants within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 2000; 12: 1232-1235.
18. Veal N, Oberti F, Moal F etal. Splenic-renal shunt blood flow is an accurate index of collateral circulation in different models of portal hypertension and after pharmacological changes in rats. J. Hepatol. 2000; 32: 434-440.
19. Saukkonen K, Lakkisto P, Kaunisto MA etal. Heme oxygenase 1 variants and plasma concentrations in critically ill patients. Shock 2010; 34: 558-564.
20. Song F, Li X, Zhang M etal. Association between heme oxygenase-1 gene promoter variants and type 2 diabetes in a Chinese population. Am. J. Epidemiol. 2009; 170: 747-756.
21. Buis CI, van der Steeege G, Visser DS etal. Heme oxygenase-1 genotype of the donor is associated with graft survival after liver transplantation. Am. J. Transplant. 2007; 8: 377-385.
22. Tugues S, Fernandez-Varo G, Munozluque J etal. Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology 2007; 46: 1919-1926.
23. Mejias M, Garcia-Pras E, Tiani C, Miquel R, Bosch J, Fernandez M. Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology 2009; 49: 1245-1256.
24. Angermayr B, Mejias M, Gracia-Sancho J etal. Heme oxygenase attenuates oxidative stress and inflammation, and increases VEGF expression in portal hypertensive rats. J. Hepatol. 2006; 44: 1033-1039.
25. Desideri G, Ferri C. Circulating vascular endothelial growth factors levels are decreased in patients with chronic hepatitis and liver cirrhosis depending on the degree of hepatic damage. Clin. Sci. 2000; 99: 159-160.
26. Akiyoshi F, Sata M, Suzuki H etal. Serum vascular endothelial growth factor levels in various liver diseases. Dig. Dis. Sci. 1998; 43: 41-45.
27. Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J. Cell Sci. 2001; 114: 853-865.